Companies are now looking at RIPK1 inhibitors for diseases like neurodegeneration and even cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery
Scientific Reports Open Access 03 August 2021
-
Discovery of a cooperative mode of inhibiting RIPK1 kinase
Cell Discovery Open Access 01 June 2021
-
Primidone blocks RIPK1-driven cell death and inflammation
Cell Death & Differentiation Open Access 03 December 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Death by inflammation: drug makers chase the master controller. Nat Biotechnol 37, 111–113 (2019). https://doi.org/10.1038/s41587-019-0023-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0023-4
This article is cited by
-
TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery
Scientific Reports (2021)
-
Discovery of a cooperative mode of inhibiting RIPK1 kinase
Cell Discovery (2021)
-
Primidone blocks RIPK1-driven cell death and inflammation
Cell Death & Differentiation (2021)
-
Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation
Nature Communications (2020)
-
A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanisms
Cell Death & Disease (2019)